Literature DB >> 24015157

Recovery of Viable Bacteria from Probiotic Products that Target Oral Health.

Jeffrey A Banas1, Eric T Popp.   

Abstract

Probiotic therapy has predominantly been directed toward promoting and maintaining intestinal health. In recent years, however, probiotic regimens that target oral health have appeared on the market. These regimens are often delivered in the form of lozenges. Despite the oral health claims made by the manufacturers of these products, there is little independent evidence in the literature to support such claims. In theory, probiotic organisms can be beneficial by several different means including direct inhibition of pathogens and boosting of the host immune response, with the underlying assumption that these mechanisms require a critical number of viable organisms. In this study, five brands of probiotics marketed for oral health were tested for the recovery of viable bacteria. For only one brand could viable bacteria be recovered within one log of the manufacturer's stated starting amount of bacteria. Nearly a billion viable bacteria could be recovered from a lozenge of this brand. The other brands claimed similar starting amounts of bacteria at the time of manufacture but at least a three-log drop off was observed in the amount of viable bacteria recovered from those products. Refrigeration of the probiotics significantly improved the recovery for one brand, but recoveries for all but one brand remained below the recommended daily dosage for probiotic regimens. It is concluded that probiotic brands differ significantly in the quantities of bacteria that remain viable with most failing to meet recommended dosage targets.

Entities:  

Year:  2013        PMID: 24015157      PMCID: PMC3762494          DOI: 10.1007/s12602-013-9142-2

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  14 in total

1.  Probiotic metabolites from Bacillus coagulans GanedenBC30™ support maturation of antigen-presenting cells in vitro.

Authors:  Kathleen F Benson; Kimberlee A Redman; Steve G Carter; David Keller; Sean Farmer; John R Endres; Gitte S Jensen
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

Review 2.  Recent advances in the role of probiotics in human inflammation and gut health.

Authors:  Prithy Rupa; Yoshinori Mine
Journal:  J Agric Food Chem       Date:  2012-08-16       Impact factor: 5.279

3.  Safety assessment of ProBiora3, a probiotic mouthwash: subchronic toxicity study in rats.

Authors:  Jeffrey D Hillman; Emily McDonell; Charles H Hillman; Robert T Zahradnik; Madhu G Soni
Journal:  Int J Toxicol       Date:  2009 Sep-Oct       Impact factor: 2.032

Review 4.  Probiotics in luminal gastroenterology: the current state of play.

Authors:  J M Andrews; M Tan
Journal:  Intern Med J       Date:  2012-12       Impact factor: 2.048

5.  Genome sequence of the bacteriocin-producing oral probiotic Streptococcus salivarius strain M18.

Authors:  Nicholas C K Heng; Nurul S Haji-Ishak; Alaina Kalyan; Andrew Y C Wong; Marija Lovric; Joanna M Bridson; Julia Artamonova; Jo-Ann L Stanton; Philip A Wescombe; Jeremy P Burton; Mary P Cullinan; John R Tagg
Journal:  J Bacteriol       Date:  2011-11       Impact factor: 3.490

Review 6.  Prebiotics, probiotics and digestive health.

Authors:  Maya Balakrishnan; Martin H Floch
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-11       Impact factor: 4.294

7.  Influence of the probiotic Streptococcus salivarius strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial.

Authors:  Jeremy P Burton; Bernadette K Drummond; Chris N Chilcott; John R Tagg; W Murray Thomson; John D F Hale; Philip A Wescombe
Journal:  J Med Microbiol       Date:  2013-02-28       Impact factor: 2.472

8.  Antibacterial activity of probiotic candidates for oral health.

Authors:  J Samot; C Badet
Journal:  Anaerobe       Date:  2012-12-01       Impact factor: 3.331

9.  Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media.

Authors:  Francesco Di Pierro; Guido Donato; Federico Fomia; Teresa Adami; Domenico Careddu; Claudia Cassandro; Roberto Albera
Journal:  Int J Gen Med       Date:  2012-11-30

10.  Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice.

Authors:  Leo R Fitzpatrick; Jeffrey S Small; Wallace H Greene; Kelly D Karpa; Sean Farmer; David Keller
Journal:  Gut Pathog       Date:  2012-10-22       Impact factor: 4.181

View more
  3 in total

Review 1.  Probiotics in dietary guidelines and clinical recommendations outside the European Union.

Authors:  Stephan Ebner; Linda N Smug; Wolfgang Kneifel; Seppo J Salminen; Mary Ellen Sanders
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 2.  The ecological community of commensal, symbiotic, and pathogenic gastrointestinal microorganisms - an appraisal.

Authors:  Seraj Zohurul Haque; Mainul Haque
Journal:  Clin Exp Gastroenterol       Date:  2017-05-05

3.  Assessing the drug resistance profiles of oral probiotic lozenges.

Authors:  Yi Wang; Jingya Dong; Junyi Wang; Wei Chi; Wei Zhou; Qiwen Tian; Yue Hong; Xuan Zhou; Hailv Ye; Xuechen Tian; Rongdang Hu; Aloysius Wong
Journal:  J Oral Microbiol       Date:  2022-01-07       Impact factor: 5.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.